ArticleGene therapy2003
Hypoxia-mediated tumour targeting.
Article in Gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 94 citations in OpenAlex.
- Cell line development for continuous high cell density biomanufacturing: Exploiting hypoxia for improved productivity.Metabolic engineering communications · 2021Article
- HIF1α promotes prostate cancer progression by increasing ATG5 expression.Animal cells and systems · 2019Article
- A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.Scientific reports · 2018Article
- Endothelial cell calpain as a critical modulator of angiogenesis.Biochimica et biophysica acta. Molecular basis of disease · 2017Review
- Quantification of hypoxia-related gene expression as a potential approach for clinical outcome prediction in breast cancer.PloS one · 2017Article
- Hypoxia-inducible tumour-specific promoters as a dual-targeting transcriptional regulation system for cancer gene therapy.Ecancermedicalscience · 2017Review
- Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment.Cancer letters · 2016Review
- A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization.Investigative ophthalmology & visual science · 2014Article
- Hypoxia-targeted triple suicide gene therapy radiosensitizes human colorectal cancer cells.Oncology reports · 2014Article
- Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer.Cancer biology & therapy · 2013Article
- Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2012Article
- Construction of a novel vector expressing the fusion suicide gene yCDglyTK and hTERT-shRNA and its antitumor effects.Experimental and therapeutic medicine · 2012Article
- Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo.Journal of experimental & clinical cancer research : CR · 2012Article
- Adenoviral targeting of gene expression to tumors.Cancer gene therapy · 2010Article
- Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours.Gene therapy · 2010Article
- Imaging and Targeting of the Hypoxia-inducible Factor 1-active Microenvironment.Journal of toxicologic pathology · 2009Article
- Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses.PloS one · 2008Article
- Robust hypoxia-selective regulation of a retinal pigment epithelium-specific adeno-associated virus vector.Molecular vision · 2008Article
- Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts.British journal of cancer · 2007Article
- p53-expressing conditionally replicative adenovirus CNHK500-p53 against hepatocellular carcinoma in vitro.World journal of gastroenterology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia is a common physiological feature of tumours. It activates a signalling cascade that culminates in the stabilization of the HIF-1 transcription factor and activation of genes that possess a hypoxia response element (HRE). We have used an optimized hypoxia responsive promoter (OBHRE) to investigate hypoxia-targeted gene expression in vivo in the context of an adenovirus vector. The OBHRE promoter showed limited activity in the liver or spleen such that expression was 1000-fold lower than that driven by the strong CMV/IE promoter. However, in the context of the tumour microenvironment, the OBHRE promoter achieved expression levels comparable to that of the CMV/IE promoter. Next, we showed that an adenovirus expressing the human cytochrome P450 (CYP2B6) regulated by the OBHRE promoter delays tumour growth in response to the prodrug cyclophosphamide (CPA). Finally, we exploited the hepatotropism of adenovirus to investigate whether the OBHRE promoter could mitigate the hepatotoxicity of a recombinant adenovirus expressing thymidine kinase (TK) in the context of the prodrug ganciclovir (GCV). High-dose Ad.CMVTK/GCV treatment caused significant liver necrosis whereas the same dose of Ad.HRETK was well tolerated. These in vivo data demonstrate that hypoxia-targeted gene expression via the OBHRE promoter can be used to increase the therapeutic window of cytotoxic cancer gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.